Hemodynamic Evaluation of Nonselective -Blockers in Patients with Cirrhosis and Refractory Ascites

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2018 Jun 5

PMID 29861720

Citations 2

Authors

Alberto Ferrarese

Valerie Tikhonoff

Edoardo Casiglia

Paolo Angeli

Silvano Fasolato

Diego Faggian

Alberto Zanetto

Giacomo Germani

Francesco Paolo Russo

Patrizia Burra

Marco Senzolo

Affiliations

Soon will be listed here.

Abstract

Background: Nonselective -blockers (NSBB) have been associated with increased incidence of paracentesis-induced circulatory dysfunction (PICD) and reduced survival in patients with cirrhosis and refractory ascites.

Aim: To prospectively evaluate a hemodynamic response to NSBB in cirrhotics listed for liver transplantation with refractory ascites undergoing large volume paracentesis (LVP).

Methods: Patients with cirrhosis and refractory ascites, with an indication to start NSBB in primary prophylaxis for variceal bleeding, were enrolled. During two consecutive LVP, while being, respectively, off and on NSBB, cardiac output (CO), systemic vascular resistances (SVR), peripheral vascular resistances (PVR), and plasma renin activity (PRA) were noninvasively assessed.

Results: Seventeen patients were enrolled, and 10 completed the study. Before NSBB introduction, SVR (1896 to 1348 dyn·s·cm; = 0.028) and PVR (47 to 30 mmHg·min·dl·ml; = 0.04) significantly decreased after LVP, while CO showed an increasing trend (3.9 to 4.5 l/m; = 0.06). After NSBB introduction, LVP was not associated with a significant increase in CO (3.4 to 3.8 l/m; = 0.13) nor with a significant decrease in SVR (2002 versus 1798 dyn·s·cm; = 0.1). Incidence of PICD was not increased after NSBB introduction.

Conclusion: The negative inotropic effect of NSBB was counterbalanced by a smaller decrease of vascular resistances after LVP, probably due to splanchnic 2-blockade. This pilot study showed that NSBB introduction may be void of detrimental hemodynamic effects after LVP in cirrhotics with refractory ascites.

Citing Articles

Is carvedilol superior to propranolol in patients with cirrhosis with portal hypertension: a systematic and meta-analysis.

Rajpurohit S, Musunuri B, Basthi Mohan P, Bhat G, Shetty S Drugs Context. 2025; 14.

PMID: 40017728 PMC: 11867166. DOI: 10.7573/dic.2024-11-3.

β-blockers in advanced cirrhosis: More friend than enemy.

Yoon K, Liu H, Lee S Clin Mol Hepatol. 2020; 27(3):425-436.

PMID: 33317244 PMC: 8273637. DOI: 10.3350/cmh.2020.0234.

Diuretic window hypothesis in cirrhosis: Changing the point of view.

Brito-Azevedo A World J Gastroenterol. 2019; 25(26):3283-3290.

PMID: 31341355 PMC: 6639551. DOI: 10.3748/wjg.v25.i26.3283.

References

Casiglia E, Pizziol A, Tikhonoff V, Mazza A, Di Menza G, Palatini P . The 24-hour rhythm of blood pressure differs from that of leg hemodynamics in orthotopic heart transplant recipients. Am Heart J. 2000; 140(6):941-4. DOI: 10.1067/mhj.2000.111110. View

Reiberger T, Mandorfer M . Beta adrenergic blockade and decompensated cirrhosis. J Hepatol. 2016; 66(4):849-859. DOI: 10.1016/j.jhep.2016.11.001. View

Thalheimer U, Christie J, Burroughs A . Benefits of Beta blockade beyond bleeding prophylaxis and the role of adherence. Am J Gastroenterol. 2012; 107(10):1593. DOI: 10.1038/ajg.2012.261. View

Moreau R, Delegue P, Pessione F, Hillaire S, Durand F, Lebrec D . Clinical characteristics and outcome of patients with cirrhosis and refractory ascites. Liver Int. 2004; 24(5):457-64. DOI: 10.1111/j.1478-3231.2004.0991.x. View

DAmico G, Morabito A, DAmico M, Pasta L, Malizia G, Rebora P . Clinical states of cirrhosis and competing risks. J Hepatol. 2017; 68(3):563-576. DOI: 10.1016/j.jhep.2017.10.020. View

Serste T, Melot C, Francoz C, Durand F, Rautou P, Valla D . Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010; 52(3):1017-22. DOI: 10.1002/hep.23775. View

Coll S, Vila M, Molina L, Gimenez M, Guarner C, Sola R . Mechanisms of early decrease in systemic vascular resistance after total paracentesis: influence of flow rate of ascites extraction. Eur J Gastroenterol Hepatol. 2004; 16(3):347-53. DOI: 10.1097/00042737-200403000-00016. View

Piccoli A . Identification of operational clues to dry weight prescription in hemodialysis using bioimpedance vector analysis. The Italian Hemodialysis-Bioelectrical Impedance Analysis (HD-BIA) Study Group. Kidney Int. 1998; 53(4):1036-43. DOI: 10.1111/j.1523-1755.1998.00843.x. View

Appenrodt B, Wolf A, Grunhage F, Trebicka J, Schepke M, Rabe C . Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study. Liver Int. 2008; 28(7):1019-25. DOI: 10.1111/j.1478-3231.2008.01734.x. View

10.

Runyon B . Management of adult patients with ascites due to cirrhosis: an update. Hepatology. 2009; 49(6):2087-107. DOI: 10.1002/hep.22853. View

11.

Moore K, Wong F, Gines P, Bernardi M, Ochs A, Salerno F . The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003; 38(1):258-66. DOI: 10.1053/jhep.2003.50315. View

12.

Ferrarese A, Tsochatzis E, Burroughs A, Senzolo M . Beta-blockers in cirrhosis: therapeutic window or an aspirin for all?. J Hepatol. 2014; 61(2):449-50. DOI: 10.1016/j.jhep.2014.03.038. View

13.

Sola-Vera J, Minana J, Ricart E, Planella M, Gonzalez B, Torras X . Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology. 2003; 37(5):1147-53. DOI: 10.1053/jhep.2003.50169. View

14.

Gines A, Fernandez-Esparrach G, Monescillo A, Vila C, Domenech E, Abecasis R . Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology. 1996; 111(4):1002-10. DOI: 10.1016/s0016-5085(96)70068-9. View

15.

Nasr G, Hassan A, Ahmed S, Serwah A . Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. J Cardiovasc Dis Res. 2010; 1(3):136-44. PMC: 2982202. DOI: 10.4103/0975-3583.70914. View

16.

Ge P, Runyon B . The changing role of beta-blocker therapy in patients with cirrhosis. J Hepatol. 2013; 60(3):643-53. DOI: 10.1016/j.jhep.2013.09.016. View

17.

Richard R, Lonsdorfer-Wolf E, Charloux A, Doutreleau S, Buchheit M, Oswald-Mammosser M . Non-invasive cardiac output evaluation during a maximal progressive exercise test, using a new impedance cardiograph device. Eur J Appl Physiol. 2001; 85(3-4):202-7. DOI: 10.1007/s004210100458. View

18.

Davenport A, Argawal B, Wright G, Mantzoukis K, Dimitrova R, Davar J . Can non-invasive measurements aid clinical assessment of volume in patients with cirrhosis?. World J Hepatol. 2013; 5(8):433-8. PMC: 3767842. DOI: 10.4254/wjh.v5.i8.433. View

19.

Casiglia E, Palatini P, Colangeli G, Ginocchio G, Di Menza G, Onesto C . 24 h rhythm of blood pressure and forearm peripheral resistance in normotensive and hypertensive subjects confined to bed. J Hypertens. 1996; 14(1):47-52. View

20.

Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M . Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014; 146(7):1680-90.e1. DOI: 10.1053/j.gastro.2014.03.005. View